<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011222910
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Binoven XL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VENLAFAXINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        91.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Aurobindo Pharma Limited Unit III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Limited Unit III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What is Binoven XL?</strong><br />Binoven XL contains the active substance venlafaxine. Binoven XL is an antidepressant that belongs to<br />a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of<br />medicines is used to treat depression and other conditions such as anxiety disorders. It is thought that<br />people who are depressed and/or anxious have lower levels of serotonin and noradrenaline in the<br />brain. It is not fully understood how antidepressants work, but they may help by increasing the levels of<br />serotonin and noradrenaline in the brain.<br />Binoven XL is a treatment for adults with depression. It is also a treatment for adults with the following<br />anxiety disorders: generalised anxiety disorder, social anxiety disorder (fear or avoidance of social<br />situations) and panic disorder (panic attacks). Treating depression or anxiety disorders properly is<br />important to help you get better. If it is not treated, your condition may not go away and may become<br />more serious and more difficult to treat.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Binoven XL</strong><br />&bull; If you are allergic to venlafaxine or any of the other ingredients of this medicine (listed in section 6).<br />&bull; If you are also taking, or have taken within the last 14 days, any medicines known as irreversible<br />monoamine oxidase inhibitors (MAOIs), used to treat depression or Parkinson&rsquo;s disease. Taking an<br />irreversible MAOI together with Binoven XL, can cause serious or even life-threatening side effects.<br />Also, you must wait at least 7 days after you stop taking Binoven XL before you take any MAOI (see<br />also the section entitled &ldquo;Other medicines and Binoven XL&rdquo; and the information in that section about<br />&lsquo;Serotonin Syndrome&rsquo;)<br /><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Binoven XL:<br />&bull; If you use other medicines that taken together with Binoven XL could increase the risk of developing<br />serotonin syndrome (see the section &ldquo;Other medicines and Binoven XL&rdquo;).<br />&bull; If you have eye problems, such as certain kinds of glaucoma (increased pressure in the eye).<br />&bull; If you have a history of high blood pressure.<br />&bull; If you have a history of heart problems.<br />&bull; If you have been told you have an abnormal heart rhythm<br />&bull; If you have a history of fits (seizures).<br />&bull; If you have a history of low sodium levels in your blood (hyponatraemia).<br />&bull; If you have a tendency to develop bruises or a tendency to bleed easily (history of bleeding<br />disorders or if you are pregnant see &lsquo;Pregnancy and breast-feeding&rsquo;), or if you are taking other<br />medicines that may increase the risk of bleeding e.g., warfarin (used to prevent blood clots).<br />&bull; If you have a history of, or if someone in your family has had, mania or bipolar disorder (feeling<br />over-excited or euphoric).<br />&bull; If you have a history of aggressive behaviour.<br />Binoven XL may cause a sensation of restlessness or an inability to sit or stand still during the first few<br />weeks of treatment. You should tell your doctor if this happens to you.<br />Thoughts of suicide and worsening of your depression or anxiety disorder<br />If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of harming or<br />killing yourself.<br />These thoughts may be increased when you first start taking antidepressants, since these medicines<br />all take time to work, usually about two weeks, but sometimes longer.<br />These thoughts may also occur when your dose is decreased or during discontinuation of treatment<br />with Binoven XL.<br />You may be more likely to think like this:</p><p dir="ltr">&bull; If you have previously had thoughts about killing yourself or harming yourself.<br />&bull; If you are a young adult. Information from clinical trials has shown an increased risk of suicidal<br />behaviour in young adults (less than 25 years old) with psychiatric conditions who were treated with<br />an antidepressant.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital<br />straight away.<br />You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety<br />disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression<br />or anxiety is getting worse, or if they are worried about changes in your behaviour.<br />Dry mouth<br />Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of tooth<br />decay (caries). Therefore, you should take special care in your dental hygiene.<br />Diabetes<br />Your blood glucose levels may be altered due to Binoven -ER. Therefore, the dosages of your diabetes<br />medicines may need to be adjusted.<br />Sexual problems<br />Medicines like Binoven XL (so called SSRIs/ SNRIs) may cause symptoms of sexual dysfunction (see<br />section 4). In some cases, these symptoms have continued after stopping treatment.</p><p dir="ltr"><strong>Children and adolescents</strong><br />Binoven XL should normally not be used for children and adolescents under 18 years.<br />Also, you should know that patients under 18 have an increased risk of side effects, such as suicide attempt,<br />suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they<br />take this class of medicines. Despite this, your doctor may prescribe this medicine for patients under 18<br />because he/she decides that this is in their best interests. If your doctor has prescribed this medicine<br />for a patient under 18, and you want to discuss this, please go back to your doctor. You should inform<br />your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking<br />Binoven XL. Also, the long-term safety effects concerning growth, maturation and cognitive and<br />behavioural development of this medicine in this age group has not yet been demonstrated.<br /><strong>Other medicines and Binoven XL</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Your doctor should decide whether you can take Binoven XL with other medicines.<br />Do not start or stop taking any medicines, including those bought without a prescription, natural and<br />herbal remedies, before checking with your doctor or pharmacist.<br />&bull; Monoamine oxidase inhibitors which are used to treat depression or Parkinson&rsquo;s disease must not<br />be taken with Binoven XL. Tell your doctor if you have taken these medicines within the last<br />14 days. (MAOIs: see the section &ldquo;What you need to know before you take Binoven XL&rdquo;).<br />&bull; Serotonin syndrome:<br />A potentially life‑threatening condition or Neuroleptic Malignant Syndrome (NMS)-like reactions (see the<br />section &ldquo;Possible Side Effects&rdquo;), may occur with venlafaxine treatment, particularly when taken with<br />other medicines.<br />Examples of these medicines include:<br />&bull; Triptans (used for migraine)<br />&bull; Other medicines to treat depression, for instance SNRIs, SSRIs, tricyclics, or medicines containing lithium<br />&bull; Medicines containing amphetamines (used to treat attention deficit hyperactivity disorder (ADHD),<br />narcolepsy and obesity)<br />&bull; Medicines containing linezolid, an antibiotic (used to treat infections)<br />&bull; Medicines containing moclobemide, a MAOI (used to treat depression)<br />&bull; Medicines containing sibutramine (used for weight loss)<br />&bull; Medicines containing tramadol, fentanyl, tapentadol, pethidine, or pentazocine (used to treat severe pain)<br />&bull; Medicines containing dextromethorphan (used to treat coughing)<br />&bull; Medicines containing methadone (used to treat opioid drug addiction or severe pain)<br />&bull; Medicines containing methylene blue (used to treat high levels of methaemoglobin in the blood)<br />&bull; Products containing St. John&rsquo;s Wort (also called Hypericum perforatum, a natural or herbal remedy<br />used to treat mild depression)<br />&bull; Products containing tryptophan (used for problems such as sleep and depression)<br />&bull; Antipsychotics (used to treat a disease with symptoms such as hearing, seeing or sensing things<br />which are not there, mistaken beliefs, unusual suspiciousness, unclear reasoning and becoming<br />withdrawn) buprenorphine-containing medical products. These medicines may interact with Binoven<br />XL and you may experience symptoms such as involuntary, rhythmic contractions of muscles,<br />including the muscles that control movement of the eye, agitation, hallucinations, coma, excessive<br />sweating, tremor, exaggeration of reflexes, increased muscle tension, body temperature above<br />38&deg;C. Contact your doctor when experiencing such symptoms.</p><p dir="ltr">Signs and symptoms of serotonin syndrome may include a combination of the following: restlessness,<br />hallucinations, loss of coordination, fast heartbeat, increased body temperature, fast changes in blood<br />pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting.<br />In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant Syndrome (NMS).<br />Signs and symptoms of NMS may include a combination of fever, fast heartbeat, sweating, severe<br />muscle stiffness, confusion, increased muscle enzymes (determined by a blood test).<br />Tell your doctor immediately, or go to the casualty department at your nearest hospital if you<br />think serotonin syndrome is happening to you.<br />You must tell your doctor if you are taking medicines that can affect your heart rhythm.<br />Examples of these medicines include:<br />&bull; Antiarrhythmics such as quinidine, amiodarone, sotalol or dofetilide (used to treat abnormal heart rhythm)<br />&bull; Antipsychotics such as thioridazine (See also Serotonin syndrome above)<br />&bull; Antibiotics such as erythromycin or moxifloxacin (used to treat bacterial infections)<br />&bull; Antihistamines (used to treat allergy)<br />The following medicines may also interact with Binoven XL and should be used with caution. It is<br />especially important to mention to your doctor or pharmacist if you are taking medicines containing:<br />&bull; Ketoconazole (an antifungal medicine)<br />&bull; Haloperidol or risperidone (to treat psychiatric conditions)<br />&bull; Metoprolol (a beta blocker to treat high blood pressure and heart problems).<br /><strong>Binoven XL with food, drink and alcohol</strong><br />Binoven XL should be taken with food (see section 3 &ldquo;How to take Binoven XL&rdquo;).<br />You should avoid alcohol while you are taking Binoven XL.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking this medicine. You should use Binoven XL only after<br />discussing the potential benefits and the potential risks to your unborn child with your doctor.<br />Make sure your midwife and/or doctor knows you are on venlafaxine. When taken during pregnancy,<br />similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent<br />pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish.<br />These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your<br />baby you should contact your midwife and/or doctor immediately.<br />If you are taking this medicine during pregnancy, in addition to having trouble breathing, another symptom<br />your baby might have when it is born is not feeding properly. If your baby has these symptoms when it<br />is born and you are concerned, contact your doctor and/or midwife who will be able to advise you.<br />If you take Binoven XL near the end of your pregnancy there may be an increased risk of heavy vaginal<br />bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife<br />should be aware that you are taking Binoven XL so they can advise you. Binoven XL passes into breast<br />milk. There is a risk of an effect on the baby. Therefore, you should discuss the matter with your doctor,<br />and he/she will decide whether you should stop breast‑feeding or stop the therapy with this medicine.</p><p dir="ltr"><strong>Driving and using machines</strong><br />Do not drive or use any tools or machines until you know how this medicine affects you.<br />Binoven XL capsules contain sugar spheres, containing sucrose. If you have been told by your doctor<br />that you have an intolerance for some sugars, contact your doctor before taking this medicinal product.<br /><strong>Binoven XL contains Sodium</strong><br />This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially<br />&lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if<br />you are not sure.<br />The usual recommended starting dose for treatment of depression, generalised anxiety disorder and<br />social anxiety disorder is 75 mg per day. The dose can be raised by your doctor gradually, and if<br />needed, even up to a maximum dose of 375 mg daily for depression. If you are being treated for panic<br />disorder, your doctor will start with a lower dose (37.5 mg) and then increase the dose gradually. The<br />maximum dose for generalised anxiety disorder, social anxiety disorder and panic disorder is 225 mg/day.<br />Take BINOVEN XL at approximately the same time each day, either in the morning or in the evening.<br />Capsules must be swallowed whole with fluid and not opened, crushed, chewed or dissolved.<br />Binoven XL should be taken with food.<br />If you have liver or kidney problems, talk to your doctor, since your dose of this medicine may need to<br />be different.<br />Do not stop taking this medicine without talking to your doctor (see the section &ldquo;If you stop taking<br />Binoven XL&rdquo;).<br />If you take more Binoven XL than you should<br />Call your doctor or pharmacist immediately if you take more of this medicine than the amount<br />prescribed by your doctor.<br />The symptoms of a possible overdose may include a rapid heartbeat, changes in level of alertness<br />(ranging from sleepiness to coma), blurred vision, seizures or fits, and vomiting.<br />If you forget to take Binoven XL<br />If you miss a dose, take it as soon as you remember. However, if it is time for your next dose, skip the<br />missed dose and take only a single dose as usual. Do not take a double dose to make up for a forgotten<br />dose. Do not take more than the daily amount of Binoven XL that has been prescribed for you in one day.<br />If you stop taking Binoven XL<br />Do not stop taking your treatment or reduce the dose without the advice of your doctor even if you feel<br />better. If your doctor thinks that you no longer need Binoven XL, he/ she may ask you to reduce your<br />dose slowly before stopping treatment altogether. Side effects are known to occur when people stop<br />using this medicine, especially when it is stopped suddenly or the dose is reduced too quickly. Some<br />patients may experience symptoms such as suicidal thoughts, aggressiveness, tiredness, dizziness,<br />lightheadedness, headache, sleeplessness, nightmares, dry mouth, loss of appetite, nausea, diarrhoea,<br />nervousness, agitation, confusion, ringing in the ears, tingling or rarely electric shock sensations,<br />weakness, sweating, seizures, or flu-like symptoms, problems with eyesight and increase in blood<br />pressure (which can cause headache, dizziness, ringing in the ears, sweating, etc).<br />Your doctor will advise you on how you should gradually discontinue Binoven XL treatment. This can<br />take a period of several weeks or months. In some patients, discontinuation may need to occur very<br />gradually over periods of months or longer.<br />If you experience any of these or other symptoms that are troublesome, ask your doctor for further advice.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If any of the following happen, do not take more Binoven XL. Tell your doctor immediately, or go to<br />the casualty department at your nearest hospital:<br />Uncommon (may affect up to 1 in 100 people)<br />&bull; Swelling of the face, mouth, tongue, throat, hands, or feet, and/or a raised itchy rash (hives), trouble<br />swallowing or breathing<br />Rare (may affect up to 1 in 1,000 people)<br />&bull; Chest tightness, wheezing, trouble swallowing or breathing<br />&bull; Severe skin rash, itching, or hives (elevated patches of red or pale skin that often itch)<br />&bull; Signs and symptoms of serotonin syndrome which may include restlessness, hallucinations, loss of<br />coordination, fast heartbeat, increased body temperature, fast changes in blood pressure,<br />overactive reflexes, diarrhoea, coma, nausea, vomiting.<br />&bull; In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant Syndrome (NMS).<br />Signs and symptoms of NMS may include a combination of fever, fast heartbeat, sweating, severe<br />muscle stiffness, confusion, increased muscle enzymes (determined by a blood test).<br />&bull; Signs of infection, such as high temperature, chills, shivering, headaches, sweating, flu-like symptoms.<br />This may be the result of a blood disorder which leads to an increased risk of infection.<br />&bull; Severe rash, which may lead to severe blistering and peeling of the skin.<br />&bull; Unexplained muscle pain, tenderness or weakness. This may be a sign of rhabdomyolysis.<br />Frequency not known (cannot be estimated from the available data)<br />&bull; Signs and symptoms of a condition called &ldquo;stress cardiomyopathy&rdquo; which may include chest pain,<br />shortness of breath, dizziness, fainting, irregular heartbeat.<br />Other side effects that you should tell your doctor about include (The frequency of these side<br />effects are included in the list &ldquo;Other side effects that may occur&rdquo; below):<br />&bull; Coughing, wheezing and shortness of breath which may be accompanied by a high temperature<br />&bull; Black (tarry) stools or blood in stools<br />&bull; Itchiness, yellow skin or eyes, or dark urine, which may be symptoms of inflammation of the liver (hepatitis)<br />&bull; Heart problems, such as fast or irregular heart rate, increased blood pressure<br />&bull; Eye problems, such as blurred vision, dilated pupils<br />&bull; Nerve problems, such as dizziness, pins and needles, movement disorder (muscle spasms or<br />stiffness), seizures or fits<br />&bull; Psychiatric problems, such as hyperactivity and feeling unusually overexcited.<br />&bull; Withdrawal effects (see the section &ldquo;How to take Binoven XL, if you stop taking Binoven XL&rdquo;).<br />&bull; Prolonged bleeding &ndash; if you cut or injure yourself, it may take slightly longer than usual for bleeding<br />to stop.</p><p dir="ltr">Do not be concerned if you see small white balls or granules in your stools after taking this<br />medicine. Inside Binoven XL capsules are spheroids (small white balls) that contain the active<br />ingredient (venlafaxine). These spheroids are released from the capsule into your stomach. As<br />they travel through your stomach and intestines, venlafaxine is slowly released. The spheroid<br />&ldquo;shell&rdquo; does not dissolve and is passed out in your stools. So, even though you may see<br />spheroids in your stools, your dose of medicine has been absorbed.<br />Other side effects that may occur<br />Very common (may affect more than 1 in 10 people)<br />&bull; Dizziness; headache, drowsiness<br />&bull; Insomnia<br />&bull; Nausea; dry mouth, constipation<br />&bull; Sweating (including night sweats)<br />Common (may affect up to 1 in 10 people)<br />&bull; Appetite decreased<br />&bull; Confusion; feeling separated (or detached) from yourself; lack of orgasm; decreased libido;<br />agitation, nervousness; abnormal dreams<br />&bull; Tremor, a sensation of restlessness or an inability to sit or stand still, pins and needles altered taste<br />sensation; increased muscle tonus.<br />&bull; Visual disturbance including blurred vision; dilated pupils; inability of the eye to automatically<br />change focus from distant to near objects<br />&bull; Ringing in the ears (tinnitus)<br />&bull; Fast heartbeat, palpitations<br />&bull; Increase in blood pressure; flushing<br />&bull; Shortness of breath; yawning<br />&bull; Vomiting; diarrhoea<br />&bull; Mild rash, itching<br />&bull; Increased frequency in urination; inability to pass urine, difficulties passing urine<br />&bull; Menstrual irregularities such as increased bleeding or increased irregular bleeding; abnormal<br />ejaculation/orgasm (males); erectile dysfunction (impotence)<br />&bull; Weakness (asthenia); fatigue; chills<br />&bull; Weight gain; weight loss<br />&bull; Increased cholesterol</p><p dir="ltr">Uncommon (may affect up to 1 in 100 people)<br />&bull; Over activity, racing thoughts and decreased need for sleep (mania)<br />&bull; Hallucinations; feeling separated (or detached) from reality; abnormal orgasm; lack of feeling or<br />emotion; feeling overexcited; grinding of the teeth<br />&bull; Fainting; involuntary movements of the muscles; impaired coordination and balance<br />&bull; Feeling dizzy (particularly when standing up too quickly) ; decrease in blood pressure<br />&bull; Vomiting blood, black tarry stools (faeces) or blood in stools; which can be a sign of internal bleeding<br />&bull; Sensitivity to sunlight; bruising; abnormal hair loss<br />&bull; Inability to control urination<br />&bull; Stiffness, spasms and involuntary movements of the muscles<br />&bull; Slight changes in blood levels of liver enzymes<br />Rare (may affect up to 1 in 1,000 people)<br />&bull; Seizures or fits<br />&bull; Coughing, wheezing and shortness of breath which may be accompanied by a high temperature<br />&bull; Disorientation and confusion often accompanied by hallucination (delirium)<br />&bull; Excessive water intake (known as SIADH)<br />&bull; Decrease in blood sodium levels<br />&bull; Severe eye pain and decreased or blurred vision<br />&bull; Abnormal, rapid or irregular heartbeat, which could lead to fainting<br />&bull; Severe abdominal or back pains (which could indicate a serious problem in the gut, liver or pancreas)<br />&bull; Itchiness, yellow skin or eyes, dark urine, or flu-like symptoms, which are symptoms of inflammation<br />of the liver (hepatitis)<br />Very rare (may affect up to 1 in 10,000 people)<br />&bull; Prolonged bleeding, which may be a sign of reduced number of platelets in your blood, leading to<br />an increased risk of bruising or bleeding<br />&bull; Abnormal breast milk production<br />&bull; Unexpected bleeding, e.g. bleeding gums, blood in the urine or in vomit, or the appearance of<br />unexpected bruises or broken blood vessels (broken veins)<br />Frequency not known(cannot be estimated from the available data)<br />&bull; Suicidal ideation and suicidal behaviours; cases of suicidal ideation and suicidal behaviours have<br />been reported during venlafaxine therapy or early after treatment discontinuation (see section 2,<br />What you need to know before you take Binoven XL)<br />&bull; Aggression<br />&bull; Vertigo<br />&bull; Heavy vaginal bleeding shortly after birth (postpartum haemorrhage), see Pregnancy and breastfeeding<br />in section 2 for more information.<br />Binoven XL sometimes causes unwanted effects that you may not be aware of, such as increases in<br />blood pressure or abnormal heart beat; slight changes in blood levels of liver enzymes, sodium or<br />cholesterol. More rarely, Binoven XL may reduce the function of platelets in your blood, leading to an<br />increased risk of bruising or bleeding. Therefore, your doctor may wish to do blood tests occasionally,<br />particularly if you have been taking Binoven XL for a long time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children<br />- Do not use this medicine after the expiry date, which is stated on the blister and carton after &ldquo;EXP<br />The expiry date refers to the last day of that month<br />Store below 30&deg;C<br />- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to<br />throw away medicines no longer use. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">What Binoven XL contains<br />&bull; The active substance is venlafaxine.<br />Each Prolonged-release capsule contains 75 mg of venlafaxine (as hydrochloride).<br />Each Prolonged-release capsule contains 150 mg of venlafaxine (as hydrochloride).<br />&bull; Other ingredients in the capsules are: Sugar spheres (containing sucrose), hypromellose, talc and<br />ethyl cellulose.<br />The capsule shell contains:<br />Cap: Gelatine, iron oxide red (E172), titanium dioxide (E171) and sodium lauryl sulphate.<br />Body: Gelatin, iron oxide red (E172), titanium dioxide (E171), sodium lauryl sulfate.<br />The printing ink contains: Shellac and black iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Binoven XL 75 mg prolonged-release capsules, hard
White to off-white spherical to oval pellets filled in Empty hard gelatin capsule shell (size ‘1’) of Opaque Peach
color cap and Opaque Peach color body imprinted with “E” on cap and “74” on the body with edible black ink.
Binoven XL 150 mg prolonged-release capsules, hard
White to off-white spherical to oval pellets filled in Empty hard gelatin capsule shell (size ‘0’) of Opaque
Dark orange color cap and Opaque Dark orange color body imprinted with “E” on cap and “89” on the
body with edible black ink.
Binoven XL Capsules are supplied in 10’s pack (10’s blister x 3)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Manufacturing Site:<br />Aurobindo Pharma Limited,<br />Unit III, Survey No. 313 &amp; 314, Bachupally,<br />Bachupally Mandal, Medchal-Malkajgiri District,<br />Telangana State, India.<br />Marketing Authorization Holder:<br />Aurobindo Pharma Saudi Arabia Limited,<br />Jeddah, Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 08/2021, Version number is 00.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو بينوفين إكس إل؟<br />يحتوي بينوفين إكس إل على المادة الفعالة فينلافاكسين. بينوفين إكس إل هو مضاد للاكتئاب ينتمي لمجموعة من الأدوية تُسمى مثبطات إعادة أخذ سيروتونين ونوريبينفرين&nbsp;(SNRIs).</p><p>تُستخدم هذه المجموعة من الأدوية لعلاج الاكتئاب وبعض الحالات الأخرى مثل اضطرابات القلق. من المعتقد&nbsp;أن الأشخاص المكتئبين أو القلقين أو كلاهما لديهم مستويات منخفضة من سيروتونين ونورادرينالين في الدماغ. آلية عمل مضادات الاكتئاب غير معلومة بصورة كاملة، ولكنها قد تُساعد عن طريق العمل على زيادة مستويات سيروتونين ونورادرينالين في الدماغ.<br />يُستعمل بينوفين إكس إل لعلاج البالغين المصابين بالاكتئاب، كما أنه يُستخدم لعلاج البالغين المصابين باضطرابات القلق التالية: اضطراب القلق المتعمم<br />واضطراب القلق المجتمعي ) خوف المواقف الاجتماعية أو تجنبها (واضطراب الهلع ) نوبات الهلع(. من المهم أن تعالج الاكتئاب أو اضطرابات القلق<br />بصورة صحيحة كي تشعر بالتحسن، وفي حالة عدم علاجها، قد لا تتحسن حالتك، وربما تصبح أكثر خطورة ويصبح علاجها أكثر صعوبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تأخذ بينوفين إكس إل<br />&nbsp;&bull; إذا كانت لديك حساسية تجاه فينلافاكسين أو أي من المكونات الأخرى لهذا الدواء( المذكورة في القسم 6 )</p><p>&bull; إذا كنت تأخذ أو أخذت خلال الأربعة عشر يومًا الأخيرة أي أدوية تعرف باسم مثبطات أوكسيديز أحادي الأمين&nbsp;(MAOIs) غير الارتجاعية&nbsp;</p><p>التي تُستخدم لعلاج الاكتئاب أو مرض باركينسون. قد يتسبب أخذ مثبطات أوكسيديز أحادي الأمين&nbsp;&nbsp;(MAOIs) غير الارتجاعية&nbsp;مع بينوفين إكس&nbsp;إل في حدوث آثار جانبية خطيرة أو مميتة. وكذلك يجب أن تنتظر سبعة أيام على الأقل بعد التوقف عن أخذ بينوفين إكس إل كي تتمكن من أخذ&nbsp;أي مثبط لأوكسيديز أحادي الأمين&nbsp;(MAOIs)انظر أيضًا القسم &ldquo; الأدوية الأخرى وبينوفين إكس إل&rdquo;، وكذلك المعلومات المذكورة في هذا القسم حول &ldquo; متلازمة السيروتونين &rdquo;</p><p>التحذيرات والاحتياطات<br />تحدث مع طبيبك أو الصيدلي قبل أخذ بينوفين إكس إل:<br />&bull; إذا كنت تستعمل أدوية أخرى بالتزامن مع بينوفين إكس إل من شأنها أن تُزيد من خطر الإصابة بمتلازمة السيروتونين ) انظر القسم &ldquo; الأدوية<br />الأخرى وبينوفين إكس إل (&rdquo;.<br />&bull; إذا كانت لديك مشاكل بالعينين مثل بعض أنواع الزرق ) زيادة الضغط داخل العين(.<br />&bull; إذا أُصبت مسبقًا بارتفاع ضغط الدم.<br />&bull; إذا عانيت مسبقًا من مشاكل بالقلب.<br />&bull; إذا علمت أن لديك نبضات قلب غير منتظمة<br />&bull; إذا أُصبت مسبقًا بنوبات ) تشنجات(.<br />&bull; إذا عانيت مسبقًا من انخفاض مستويات الصوديوم بالدم ) قلة صوديوم الدم(.<br />&bull; إذا كانت لديك قابلية للإصابة بالكدمات أو النزف بسهولة ) تاريخ من اضطرابات النزف، أو إن كنتِ حام ،ًال انظرِ قسم &ldquo; الحمل والرضاعة<br />الطبيعية (&rdquo;، أو إذا كنت تأخذ أدوية أخرى قد تُزيد من خطر النزف. على سبيل المثال، وارفارين ) يُستخدم لعلاج تخثرات الدم(.<br />&bull; إذا أُصبت مسبقًا أنت أو شخص ما في عائلتك بالهوس أو الاضطراب ثنائي القطب ) الشعور بالإثارة الشديدة أو النشوة(.<br />&bull; إذا عانيت مسبقًا من سلوك عدائي.<br />قد يتسبب بينوفين إكس إل بشعور بعدم الراحة أو عدم القدرة على الجلوس أو البقاء ساكنًا أثناء الأسابيع القليلة الأولى من العلاج. يجب أن تُعلم طبيبك<br />إذا حدث لك ذلك.<br />أفكار الانتحار وتفاقم حالة الاكتئاب أو اضطراب القلق<br />إذا كنت مصابًا بالاكتئاب أو اضطرابات القلق أو كلاهما، قد تعصف بذهنك أحيانًا أفكارًا تتعلق بإيذاء نفسك أو الانتحار.<br />وقد تزداد هذه الأفكار عندما تأخذ مضادات الاكتئاب لأول مرة، حيث أن هذه الأدوية جميعًا تأخذ بعض الوقت كي تعمل، خلال أسبوعين تقريبًا في<br />العادة، وأكثر في بعض الأحيان.<br />قد تظهر هذه الأفكار أيضًا عند خفض الجرعة، أو خلال إيقاف العلاج ببينوفين إكس إل.<br />قد تنتابك مثل هذه الأفكار:<br />&bull; إذا انتابتك أفكار بصورة مسبقة تتعلق بالانتحار أو إيذاء نفسك.<br />&bull; إذا كنت شابًا صغير السن، حيث اظهرت المعلومات الناتجة من الدراسات الإكلينيكية زيادة خطر الإصابة بالسلوك الانتحاري لدي الشباب صغار<br />السن ) الأقل من 25 عامًا (المصابين بحالات نفسية، والذين يعالجون بمضادات الاكتئاب.<br />تواصل مع طبيبك أو اذهب إلى المستشفى على الفور إذا انتابتك أفكار تتعلق بإيذاء نفسك أو الانتحار في أي وقت.<br />قد يكون مفيدًا أن تُعلم قريبًا أو صديقًا مقربًا بأنك مصاب بالاكتئاب أو اضطراب القلق، واطلب منه قراءة هذه النشرة. ويمكنك أن تطلب منهم إبداء<br />رأيهم إن كانوا يظنون أن اكتئابك أو قلقك قد تفاقم، أو إذا كانوا قلقين حول التغيرات بسلوكك</p><p>جفاف الفم<br />أُبلغ عن حدوث جفاف بالفم لدي % 10 من المرضى الذين عولجوا بفينلافاكسين. قد يُزيد ذلك من خطر تحلل الأسنان ) التسوس(، ولذلك يجب أن<br />تراعي صحة أسنانك بصورة خاصة.<br />سكري<br />قد يتسبب بينوفين إكس إل في تغير مستويات الجلوكوز بالدم، وقد تحتاج لتعديل جرعة أدوية السكري تبعًا لذلك.<br />المشاكل الجنسية<br />مثبطات إعادة أخذ سيروتونين /&rdquo;SSRIs&ldquo; قد تتسبب الأدوية المماثلة لبينوفين إكس إل ) تُدعى أيضًا مثبطات إعادة أخذ السيروتونين الانتقائية<br />في ظهور أعراض القصور الجنسي ) انظر القسم 4(. واستمرت هذه الأعراض بعد إيقاف العلاج في بعض الحالات. )&rdquo; SNRIs&ldquo; ونوريبينيفرين<br />الأطفال والمراهقون<br />لا يجب استعمال بينوفين إكس إل في المعتاد مع الأطفال والمراهقين الأقل من 18 عام،<br />وكذلك يجب أن تعلم أن المرضى الأقل من 18 عام يكونون أكثر عرضة للآثار الجانبية، مثل محاولات الانتحار والأفكار الانتحارية والعدوانية ) غالبًا<br />ما تظهر في صورة عنف وسلوك معارض وغضب (عندما يأخذون هذه الفئة من الأدوية. بالرغم من ذلك، قد يصف الطبيب هذا الدواء لمرضى أقل<br />من 18 عام؛ لأنه قرر أنه الأفضل لحالتهم. إذا وصف طبيبك هذا الدواء لمريض أقل من 18 عام وأردت مناقشة ذلك، من فضلك ارجع إلى طبيبك.<br />يجب أن تُعلم طبيبك إذا ظهرت أو تفاقمت أي من الأعراض المذكورة أعلاه عند استعمال بينوفين إكس إل مع المرضى الأقل من 18 عام. وكذلك لم<br />تُدرس آثار السلامة طويلة المدى المتعلقة بالنمو والبلوغ والتطور الإدراكي والسلوكي الناتجة عن هذا الدواء لدي هذه الفئة العمرية.<br />الأدوية الأخرى وبينوفين إكس إل<br />أعلم طبيبك إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي أدوية أخرى.<br />يجب أن يقرر طبيبك ما إذا كان في الإمكان أن تأخذ بينوفين إكس إل مع أدوية أخرى.<br />لا تأخذ أو تتوقف عن أخذ أي أدوية بما في ذلك تلك المشتراة بدون وصفة طبية وكذلك المستحضرات الطبيعية والعشبية قبل استشارة الطبيب أو<br />الصيدلي.<br />&bull; يُحظر استعمال مثبطات أوكسيديز أحادي الأمين التي تستخدم في علاج الاكتئاب أو مرض باركينسون مع بينوفين إكس إل. أعلم طبيبك إذا كنت<br />انظر القسم &ldquo; ما الذي تحتاج لمعرفته قبل :)MAOIs( تأخذ الأدوية التالية خلال الأربعة عشر يومًا الماضية. ) مثبطات أوكسيديز أحادي الأمين<br />أخذ بينوفين إكس إل؟ (&rdquo;.<br />&bull; متلازمة السيروتونين:<br />انظر القسم &ldquo; الآثار الجانبية المحتملة (&rdquo;عند العلاج ( ) NMS( قد تحدث حالة مهددة للحياة أو تفاعلات مشابهة للمتلازمة الخبيثة لمضادات الذهان<br />بفينلافاكسين، وخاصة عند أخذه مع أدوية أخرى.<br />تتضمن أمثلة تلك الأدوية ما يلي:<br />&bull; التريبتانات ) تستخدم لعلاج الصداع النصفي(<br />أو مثبطات إعادة أخذ السيروتونين الانتقائية ) SNRIs( &bull; أدوية علاج الاكتئاب الأخرى، مثل مثبطات إعادة أخذ سيروتونين ونوريبينيفرين<br />أو ثلاثيات الحلقات أو الأدوية المحتوية على الليثيوم. ) SSRIs(<br />والخدر والسمنة( ) ADHD( &bull; الأدوية المحتوية على الأمفيتامينات ) تُستخدم لعلاج اضطراب نقص الانتباه الملازم لفرط النشاط<br />&bull; الأدوية المحتوية على لينزوليد، وهو مضاد حيوي ) يُستخدم لعلاج العدوى(<br />&bull; الأدوية المحتوية على موكلوبيميد، وهو مثبط لأكسيداز أحادي الأمين ) يُستخدم لعلاج الاكتئاب(<br />&bull; الأدوية المحتوية على سيبوترامين ) يُستخدم لتخفيض الوزن(<br />&bull; الأدوية المحتوية على ترامادول أو فينتانايل أو تابينتادول أو بيثيدين أو بينتازوسين ) تُستخدم لعلاج الألم الشديد(<br />&bull; الأدوية المحتوية على ديكستروميثورفان ) تُستخدم لعلاج السعال(<br />&bull; الأدوية المحتوية على ميثادون ) تُستخدم لعلاج إدمان المخدرات الأفيونية أو الألم الشديد(<br />&bull; الأدوية المحتوية على أزرق الميثيلين ) تُستخدم لعلاج مستويات ميثيموجلوبين المرتفعة في الدم(<br />وهي مستحضر طبيعي أو عشبي يُستخدم لعلاج ،Hypericum perforatum &bull; المنتجات المحتوية على عشبة القديس جون ) وتُسمى أيضًا<br />الاكتئاب البسيط&nbsp;</p><p>&bull; المنتجات المحتوية على تريبتوفان ) يُستخدم لعلاج مشاكل النوم والاكتئاب(<br />&bull; مضادات الذهان ) تُستخدم لعلاج الأمراض ذات الأعراض المتمثلة في سماع أشياء غير موجودة أو رؤيتها أو الإحساس بها، وكذلك المعتقدات<br />الخاطئة والشك غير المعتاد والمنطق غير الواضح والانطواء(، مثل المنتجات الطبية المحتوية على بابرينورفين. قد تتداخل هذه الأدوية مع بينوفين<br />إكس إل، وقد تشعر بأعراض مثل انقباضات لا إرادية منتظمة للعضلات، بما في ذلك العضلات التي تتحكم في حركة العينين، وتهيج وهلوسات<br />وغيبوبة وتعرق زائد وارتعاش وتفاقم ردود الأفعال وزيادة التوتر العضلي وارتفاع درجة حرارة الجسم فوق 38 مئوية. تواصل مع الطبيب عند<br />شعورك بهذه الأعراض.<br />قد تتضمن علامات وأعراض متلازمة السيروتونين مجموعة من الأعراض التالية: أرق، هلاوس، فقدان تحديد الاتجاه، نبض القلب السريع، ارتفاع<br />درجة حرارة الجسم، تغيرات سريعة بضغط الدم، ردود فعل مفرطة، إسهال، غيبوبة، غثيان، قيء.<br />قد تتضمن علامات وأعراض المتلازمة الخبيثة لمضادات .)NMS( قد تُشبه متلازمة السيروتونين في أسوأ حالاتها المتلازمة الخبيثة لمضادات الذهان<br />الذهان كل من الحمى ونبض القلب السريع والتعرق وتيبس العضلات الشديد والارتباك وزيادة الإنزيمات العضلية ) تُحدد بواسطة اختبارات الدم(.<br />إذا ظننت أن تعاني من متلازمة السيروتونين، أعلم طبيبك على الفور، أو اذهب إلى قسم الإصابات بأقرب مستشفى.<br />يجب أن تُعلم طبيبك إذا كنت تأخذ أدوية من شأنها تغيير نظم القلب.<br />تتضمن أمثلة تلك الأدوية ما يلي:<br />&bull; مضادات اضطراب النظم مثل كينيدين أو أميودارون أو سوتالول أو دوفيتيليد ) تُستخدم لعلاج نظم القلب غير الطبيعي(<br />&bull; مضادات الذهان مثل ثيوريدازين ) انظر أيضًا متلازمة السيروتونين أعلاه(<br />&bull; المضادات الحيوية مثل إريثرومايسين أو موكسيفلوكساسين ) تُستخدم لعلاج العدوات البكتيرية(<br />&bull; مضادات الهيستامين ) تُستخدم لعلاج الحساسية(<br />قد تتفاعل الأدوية التالية أيضًا مع بينوفين إكس إل ويجب أن تُستخدم بحذر. من المهم بصورة خاصة أن تُعلم طبيبك أو الصيدلي إذا كنت تأخذ أدوية<br />تحتوي على:<br />&bull; كيتوكونازول ) مضاد فطري(<br />&bull; هالوبيريدول أو ريسبيريدون ) لعلاج الحالات النفسية(<br />&bull; ميتوبرولول ) كابح بيتا يُستخدم لعلاج ارتفاع ضغط الدم ومشاكل القلب(.<br />بينوفين إكس إل مع الطعام والشراب والكحول<br />يجب أخذ بينوفين إكس إل مع الطعام ) انظر القسم 3 &ldquo; كيفية أخذ بينوفين إكس إل (&rdquo;.<br />يجب تجنب الكحول أثناء أخذ بينوفين إكس إل.</p><p>الحمل والرضاعة الطبيعية<br />إذا كنتِ حام ًالأو تقومين بالإرضاع، أو يُحتمل أن تصبحين حام ًالأو تخططين لإنجاب طفل، يجب عليكِ أخذ مشورة طبيبك أو الصيدلي قبل استعمال<br />هذا الدواء. يجب أن تستعملي بينوفين إكس إل بعد مناقشة المزايا والمخاطر المحتملة على الجنين مع طبيبك.<br />تأكدي من أن القابلة أو الطبيب أو كلاهما على علم بأنك تأخذين فينلافاكسين. قد تُزيد أدوية مماثلة ) مثل مثبطات إعادة أخذ السيروتونين الانتقائية<br />مما يسبب سرعة ،)PPHN( من خطر حدوث حالة خطيرة للأطفال الرضع تُسمى ارتفاع ضغط الدم الرئوي الدائم لدي الأطفال الرضع )) SSRIs(<br />تنفس الرضيع وازرقاقه. عادة ما تبدأ هذه الأعراض خلال الأربعة وعشرين ساعة الأولى بعد الولادة. إذا حدث ذلك لطفلك، يجب أن تُبلغي القابلة أو<br />الطبيب أو كلاهما على الفور.<br />إذا كنتِ تأخذين هذا الدواء أثناء الحمل، فقد يعاني طفلك من عرض آخر بجانب صعوبة التنفس، وهو عدم التغذية الجيدة بعد الولادة. إذا عانى طفلك<br />من هذه الأعراض بعد ولادته واهتممتِ بذلك، تواصلي مع طبيبك أو القابلة أو كلاهما لأخذ المشورة.<br />إن كنتِ تأخذين بينوفين إكس إل قرب نهاية الحمل، قد يزداد خطر حدوث نزف مهبلي كثيف بعد الولادة بفترة قصيرة، وخاصة إن كان لديكِ تاريخ<br />للإصابة باضطرابات النزف. يجب أن يكون الطبيب أو القابلة على علم بأنكِ تأخذين بينوفين إكس إل حتى يستطيعون نصحك. يمر بينوفين إكس إل<br />لحليب الثدي. وقد يؤثر ذلك على الرضيع. ولذلك، يجب أن تناقشي هذا الأمر مع الطبيب، وسيقرر حينئذ ما إذا كان من اللازم إيقاف الرضاعة الطبيعية<br />أو إيقاف العلاج بهذا الدواء.<br />القيادة واستخدام الآلات<br />لا تقوم بالقيادة أو استخدام أية معدات أو آلات حتى تعلم تأثير هذا الدواء عليك.<br />تحتوي كبسولات بينوفين إكس إل على كرات سكر تحتوي بدورها على السكروز. إذا أخبرك طبيبك بعدم قدرتك على تحمل بعض السكريات، فعليك<br />الاتصال بطبيبك قبل أخذ هذا المنتج الطبي.<br />يحتوي بينوفين إكس إل على الصوديوم<br />يحتوي هذا الدواء على أقل من 1 ميللي مول من الصوديوم ) 23 مجم (لوحدة الجرعة، وهذا يعني أنه &ldquo; خالِ من الصوديوم</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ هذا الدواء دائمًا كما أخبرك طبيبك، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا.<br />جرعة البدء الموصي بها لعلاج الاكتئاب واضطراب القلق المتعمم واضطراب القلق المجتمعي هي 75 مجم لكل يوم، وقد يقوم طبيبك بزيادة الجرعة<br />تدريجيًا، وقد تصل عند الحاجة إلى جرعة قصوى مقدارها 375 مجم يوميًا لعلاج الاكتئاب. إذا كنت تُعالج من اضطراب الهلع، سيبدأ طبيبك بجرعة<br />أقل ) 37.5 مجم(، ثم سيُزيد من الجرعة تدريجيًا. الجرعة القصوى لعلاج اضطراب القلق المتعمم واضطراب القلق المجتمعي واضطراب الهلع هي<br />225 مجم/يوم.<br />خذ بينوفين إكس إل في نفس الوقت تقريبًا كل يوم، سواء كان ذلك في الصباح أو المساء، ويجب ابتلاع الكبسولات كاملة مع بعض الشراب، ولا تفتحها<br />أو تسحقها أو تمضغها أو تذيبها.<br />يجب أخذ بينوفين إكس إل مع الطعام.<br />إذا كنت تعاني من مشاكل بالكبد أو الكلى، تحدث مع طبيبك، فقد تحتاج لجرعات مختلفة من الدواء.<br />لا تتوقف عن أخذ هذا الدواء بدون إعلام طبيبك ) انظر القسم 6&ldquo; إذا توقفت عن أخذ بينوفين إكس &rdquo;.</p><p>إذا أخذت أكثر مما يجب من بينوفين إكس إل<br />تحدث مع طبيبك أو الصيدلي على الفور إذا أخذت من هذا الدواء أكثر مما وصف لك طبيبك.<br />قد تتضمن أعراض الجرعة المفرطة زيادة نبضات القلب وتغير مستوى الانتباه ) يتراوح ما بين النوم والغيبوبة (والرؤية الضبابية والنوبات أو<br />التشنجات والقيء.<br />إذا نسيت تناول بينوفين إكس إل<br />إذا نسيت أخذ جرعة، فخذها بمجرد تذكرك. ومع ذلك، إذا حل وقت الجرعة التالية، تجاوز الجرعة المنسية وخذ جرعة منفردة فقط كالمعتاد. لا تأخذ<br />جرعة مزدوجة للتعويض عن الجرعة المنسية. لا تأخذ أكثر من الجرعة اليومية الموصوفة لك من بينوفين إكس إل ليوم واحد.<br />إذا توقفت عن أخذ بينوفين إكس إل<br />لا تتوقف عن أخذ علاجك أو تُخفض الجرعة دون استشارة طبيبك، حتى لو شعرت بالتحسن. إذا قرر طبيبك أنك لم تعد بحاجة لبينوفين إكس إل، فقد<br />يطلب منك تخفيض الجرعة تدريجيًا قبل إيقاف العلاج بالكامل. من المعلوم أن الآثار الجانبية تحدث عند التوقف عن أخذ هذا الدواء، وخاصة عند<br />التوقف المفاجئ أو عند تخفيض الجرعة بسرعة. قد يعاني بعض المرضى من أعراض مثل الأفكار الانتحارية والعنف والإرهاق والدوخة والصداع<br />والأرق والكوابيس وجفاف الفم وفقدان الشهية والغثيان والإسهال والعصبية والتهيج والارتباك ورنين بالأذنين ووخز أو شعور بالصدمة الكهربية في<br />أحيان نادرة، وضعف وتعرق ونوبات أو أعراض شبيهة بالأنفلونزا، وكذلك مشاكل بالرؤية وارتفاع بضغط الدم ( قد يتسبب في الصداع والدوخة ورنين<br />بالأذنين وتعرق وما إلى ذلك).<br />سيُخبرك طبيبك بكيفية إيقاف العلاج ببينوفين إكس إل بصورة تدريجية. قد يستغرق الأمر عدة أسابيع أو شهور. وقد يحتاج الإيقاف لدي بعض المرضى<br />أن يحدث تدريجيًا بصورة كبيرة على مدار شهور أو أكثر.<br />اطلب من طبيبك النصح إذا عانيت من أي من هذه الأعراض أو غيرها، وسبب لك ذلك المشاكل.<br />اسأل طبيبك أو الصيدلي إن كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.<br />توقف عن أخذ بينوفين إكس إل إذا حدث أي من التالي. أعلم طبيبك على الفور، أو اذهب إلى قسم الإصابات بأقرب مستشفى:<br />غير شائعة )قد تؤثر على 1 لكل 100 شخص(<br />&bull; تورم الوجه أو الفم أو اللسان أو الحلق أو اليدين أو القدمين و/أو طفح مرتفع تصاحبه حكة ) شرى(، صعوبة في البلع أو التنفس<br />نادرة )قد تؤثر على 1 لكل 1,000 شخص(<br />&bull; ضيق تنفس، أزيز، صعوبة في البلع أو التنفس<br />&bull; طفح جلدي شديد، حكة أو شرى ) كتل مرتفعة من الجلد الأحمر أو الشاحب تصاحبه حكة في الغالب(<br />&bull; علامات وأعراض متلازمة السيروتونين التي قد تتضمن الأرق والهلاوس وفقدان تحديد الاتجاه ونبض القلب السريع وارتفاع درجة حرارة الجسم<br />والتغيرات السريعة بضغط الدم وردود الفعل المفرطة والإسهال والغيبوبة والغثيان والقيء.<br />قد تتضمن علامات وأعراض المتلازمة الخبيثة .)NMS( &bull; قد تُشبه متلازمة السيروتونين في أسوأ حالاتها المتلازمة الخبيثة لمضادات الذهان<br />لمضادات الذهان كل من الحمى ونبض القلب السريع والتعرق وتيبس العضلات الشديد والارتباك وزيادة الإنزيمات العضلية ) تُحدد بواسطة<br />اختبارات الدم(.<br />&bull; علامات العدوى مثل درجة الحرارة المرتفعة والقشعريرة والارتجاف والصداع والتعرق وأعراض مشابهة للإنفلونزا.<br />قد يكون ذلك نتيجة لاضطراب بالدم يؤدي إلى زيادة خطر حدوث العدوى.<br />&bull; طفح شديد قد يؤدي إلى تبثر وتقشر شديد بالجلد.<br />&bull; ألم أو ترقق أو ضعف غير مُفسر بالعضلات. قد يكون ذلك علامة لانحلال الربيدات.<br />التكرارية غير معلومة )لا يمكن تحديدها من البيانات المتاحة(<br />&bull; علامات وأعراض حالة تُسمى &ldquo; اعتلال عضلة القلب الإجهادي&rdquo;، وقد تتضمن ألم الصدر وصعوبة التنفس والدوخة والإغماء وعدم انتظام نبض القلب.<br />الآثار الجانبية الأخرى التي يجب أن تُخبر الطبيب بها ) تكرارية هذه الآثار الجانبية مُدرجة في القائمة &ldquo; الآثار الجانبية الأخرى التي قد تحدث &rdquo;<br />أدناه (تتضمن ما يلي:<br />&bull; سعال، أزيز وضيق بالتنفس قد يصاحبه ارتفاع بدرجة الحرارة<br />&bull; براز أسود ) قطراني (أو براز دموي<br />&bull; حكة أو اصفرار بالجلد أو العينين أو بول داكن، وقد تكون علامات لالتهاب الكبد ) الالتهاب الكبدي(<br />&bull; مشاكل بالقلب، مثل معدل القلب السريع أو غير المنتظم، ارتفاع ضغط الدم<br />&bull; مشاكل بالعينين، مثل الرؤية الضبابية واتساع الحدقات<br />&bull; مشاكل عصبية، مثل الدوخة والوخز واضطراب الحركة ) تشنجات العضلات أو تيبسها(، نوبات أو تشنجات<br />&bull; مشاكل نفسية، مثل فرط النشاط والشعور بانفعال شديد غير معتاد.<br />&bull; أعراض الانسحاب ) انظر القسم &ldquo; كيفية أخذ بينوفين إكس إل، إذا توقفت عن أخذ بينوفين إكس إل (&rdquo;.<br />&bull; النزف الممتد&ndash; إذا جرحت نفسك، سيستغرق النزف وقتًا أطول من المعتاد بقليل كي يتوقف.</p><p>لا تشعر بالقلق إذا رأيت كرات أو حبيبات صغيرة بيضاء في برازك بعد أخذ هذا الدواء، حيث أن كبسولات بينوفين إكس إل تحتوي على كريات<br />)كرات صغيرة بيضاء( توجد بداخلها المادة الفعالة )فينلافاكسين(. تتحرر هذه الكريات من الكبسولة إلى معدتك، ويُفرز فينلافاكسين ببطء على طول<br />رحلتها خلال معدتك وأمعاءك. الكريات &ldquo;القشرة&rdquo; لا تتحلل، وتخرج مع البراز، ولذلك فإن الجرعة تكون قد اُمتصت حتى لو رأيت هذه الكريات<br />ببرازك.<br />الآثار الجانبية الأخرى التي قد تحدث<br />شائعة جدًا )قد تؤثر على أكثر من 1 لكل 10 أشخاص(<br />&bull; دوخة، صداع، دوار<br />&bull; أرق<br />&bull; غثيان، جفاف الفم، إمساك<br />&bull; تعرق ) يتضمن التعرق الليلي(<br />شائعة )قد تؤثر على 1 لكل 10 أشخاص(<br />&bull; نقص الشهية<br />&bull; ارتباك، الشعور بالعزلة ) أو الانفصال (عن نفسك، اختفاء رعشة الجماع، نقص الرغبة الجنسية، تهيج، عصبية، أحلام غير طبيعية<br />&bull; ارتعاش، شعور بعدم الراحة أو عدم القدرة على الجلوس أو البقاء بوضع الوقوف، وخز، شعور بتغير التذوق، زيادة التوتر العضلي.<br />&bull; اضطرابات بصرية تتضمن الرؤية الضبابية واتساع حدقة العينين وعدم قدرة العين على تغيير التركيز من الأجسام البعيدة إلى القريبة بصورة<br />أوتوماتيكية<br />&bull; رنين في الأذنين ) طنين(<br />&bull; نبض قلب سريع، خفقان<br />&bull; ارتفاع ضغط الدم، دفق<br />&bull; ضيق تنفس، تثاؤب<br />&bull; قيء، إسهال<br />&bull; طفح بسيط، حكة<br />&bull; زيادة تكرارية التبول، عدم القدرة على التبول، صعوبة التبول<br />&bull; اضطرابات الدورة الشهرية مثل زيادة النزف أو زيادة النزف غير المنتظم، انتصاب/نشوة جنسية غير طبيعية ) للذكور(، خلل الانتصاب ) عنانة(<br />&bull; ضعف ) إرهاق(، إعياء، قشعريرة<br />&bull; زيادة الوزن، نقص الوزن<br />&bull; زيادة الكوليستيرول<br />غير شائعة )قد تؤثر على 1 لكل 100 شخص(<br />&bull; فرط النشاط، أفكار متلاحقة ونقص الرغبة في النوم ) هوس(<br />&bull; هلاوس، الشعور بالعزلة ) الانفصال (عن الواقع، نشوة جنسية غير طبيعية، غياب الإحساس أو العاطفة، الشعور بفرط النشاط، الجز على الأسنان<br />&bull; إغماء، حركة لا إرادية للعضلات، اضطراب تحديد الاتجاهات والتوازن<br />&bull; شعور بالدوخة ) خاصة عند الوقوف بسرعة شديدة(، انخفاض ضغط الدم<br />&bull; قيء دموي، براز أسود ) قطراني (أو براز دموي، والذي قد يكون علامة للنزف الداخلي<br />&bull; حساسية تجاه ضوء الشمس، تساقط غير طبيعي للشعر<br />&bull; عدم القدرة على التحكم في التبول<br />&bull; تيبس العضلات وتشنجها وحركتها اللا إرادية<br />&bull; تغيرات طفيفة بمستويات الإنزيمات الكبدية بالدم</p><p>نادرة )قد تؤثر على 1 لكل 1,000 شخص(<br />&bull; نوبات أو تشنجات<br />&bull; سعال، أزيز وضيق بالتنفس قد يصاحبه ارتفاع بدرجة الحرارة<br />&bull; عدم القدرة على تحديد الاتجاه وارتباك تصاحبه هلوسة في العادة ) هذيان(<br />))SIADH( &bull; رشف الماء الزائد عن الحد ) يُعرف بمتلازمة الإفراز غير المناسب للهرمون المضاد لإدرار البول<br />&bull; نقص مستويات الصوديوم بالدم<br />&bull; ألم شديد بالعينين ورؤية ضبابية أو ضعيفة<br />&bull; نبض قلب غير طبيعي أو سريع أو غير منتظم، قد يؤدي إلى الإغماء<br />&bull; ألم شديد بالبطن أو الظهر ) والذي قد يدل على مشكلة خطيرة بالقناة الهضمية أو الكبد أو البنكرياس(<br />&bull; حكة أو اصفرار بالجلد أو العينين أو بول داكن أو أعراض مشابهة للأنفلونزا، والتي قد تكون علامات لالتهاب الكبد ) الالتهاب الكبدي(<br />نادرة جدًا )قد تؤثر على 1 لكل 10,000 شخص(<br />&bull; نزف ممتد، والذي قد يكون علامة لانخفاض أعداد الصفيحات بدمك، والذي قد يؤدي إلى زيادة خطر حدوث الكدمات أو النزف<br />&bull; انتاج غير طبيعي لحليب الثدي<br />&bull; نزف غير متوقع، مثل نزف اللثة أو البول الدموي أو القيء الدموي أو ظهور كدمات غير متوقعة أو تكسر الأوعية الدموية ) تكسر الأوردة(<br />التكرارية غير معلومة )لا يمكن تحديدها من البيانات المتاحة(<br />&bull; فكرة الانتحار والسلوك الانتحاري، حيث أُبلغ عن حدوث حالات للفكر الانتحاري والسلوك الانتحاري خلال العلاج بفينلافاكسين، أو بعد إيقاف<br />العلاج بفترة قليلة ) انظر القسم 2، ما الذي يجب أن تعرفه قبل استعمال بينوفين إكس إل(<br />&bull; عنف<br />&bull; دوار<br />&bull; نزف مهبلي كثيف بعد الولادة بفترة قصيرة ) نزف ما بعد الولادة(. انظر الحمل والرضاعة الطبيعية في القسم 2 للمزيد من المعلومات.<br />قد يتسبب بينوفين إكس إل في بعض الأحيان بآثار غير مرغوبة قد لا تعلم بها، مثل ارتفاع ضغط الدم أو نبض القلب غير الطبيعي أو تغيرات طفيفة<br />بمستويات الإنزيمات الكبدية أو الصوديوم أو الكوليستيرول في الدم. وقد يتسبب بينوفين إكس إل بصورة أكثر ندرة في خفض فعالية الصفيحات بدمك،<br />مؤديًا إلى زيادة خطر حدوث الكدمات أو النزف. ولذلك، قد يرغب طبيبك في إجراء اختبارات دورية للدم، خاصة إذا كنت تأخذ بينوفين إكس إل لفترة<br />طويلة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- ابق هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.<br />يشير تاريخ انتهاء الصلاحية إلى آخر يوم في .&rdquo;EXP&ldquo; - لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المكتوب على الشريط والكرتون بعد<br />ذلك الشهر.<br />- يُحفظ في درجة حرارة أقل من 30 مئوية.<br />- لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. واسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها.<br />هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مما يتكون بينوفين إكس إل<br />&bull; المادة الفعالة هي فينلافاكسين.<br />تحتوي كل كبسولة ذات إفراز ممتد على 75 مجم فينلافاكسين ) في صورة هيدروكلوريد(.<br />تحتوي كل كبسولة ذات إفراز ممتد على 150 مجم فينلافاكسين ) في صورة هيدروكلوريد(.<br />&bull; المكونات الأخرى بالكبسولات هي: كرات السكر ) تحتوي على السكروز(، هيبروميلوز، تالك، إيثيل سيليولوز.<br />تحتوي قشرة الكبسولة على:<br />كبريتات لوريل الصوديوم. ،)E ثاني أكسيد التيتانيوم ) 171 ،E الغطاء: جيلاتين، أكسيد حديد أحمر ) 172<br />كبريتات لوريل الصوديوم. ،)E ثاني أكسيد التيتانيوم ) 171 ،E الجسم: جيلاتين، أكسيد حديد أحمر ) 172<br />يحتوي حبر الطباعة على: شيلاك، أكسيد حديد أسود ) 172.E</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو بينوفين إكس إل ومحتويات العبوة</strong><br />كبسولات صلبة ذات إفراز ممتد.<br />كبسولات بينوفين إكس إل الصلبة 75 ذات الإفراز الممتد<br />كريات مستديرة إلى بيضاوية الشكل لونها أبيض إلى أبيض معتم، بداخل غلاف كبسولة جيلاتينية صلبة فارغة ) حجم &ldquo; 1 (&rdquo;ذات غطاء بلون الخوخ<br />وعلى جسمها &ldquo; 74 &rdquo;بحبر أسود قابل للأكل. &rdquo; E&ldquo; المعتم وجسم بلون الخوخ المعتم، مطبوع على غطائها<br />كبسولات بينوفين إكس إل الصلبة 150 ذات الإفراز الممتد<br />كريات مستديرة إلى بيضاوية الشكل لونها أبيض إلى أبيض معتم، بداخل غلاف كبسولة جيلاتينية صلبة فارغة ) حجم &ldquo; 0 (&rdquo;ذات غطاء بلون برتقالي<br />وعلى جسمها &ldquo; 89 &rdquo;بحبر أسود قابل للأكل. &rdquo; E&ldquo; معتم وجسم بلون برتقالي معتم، مطبوع على غطائها<br />تُورد كبسولات بينوفين إكس إل في عبوة تحتوي على 10 قرص ) 3 أشرطة يحتوي كل منها على</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>موقع التصنيع:</strong><br />أوروبيندو فارما المحدودة،<br />مسح رقم 313 و 314 ، باشوبالي، ،III الوحدة<br />منطقة باشوبالي، حي ميدشال-مالكاجيري،<br />ولاية تيلانجانا، الهند.<br /><strong>حامل ترخيص التسويق:</strong><br />أوروبيندو فارما السعودية المحدودة،<br />جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اعتمدت هذه النشرة في 08/ 2021 ، رقم الإصدار هو 00 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Binoven XL (Venlafaxine Hydrochloride Prolonged-Release Capsules 75 mg &150 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Venlafaxine Hydrochloride Prolonged-Release Capsules 75 mg:
Each prolonged-release capsule contains 75 mg of venlafaxine (as hydrochloride).
Excipient with known effect:
Each capsule contains 87.1 mg sucrose.
Venlafaxine Hydrochloride Prolonged-Release Capsules 150 mg:
Each prolonged-release capsule contains 150 mg of venlafaxine (as hydrochloride).
Excipient with known effect:
Each capsule contains 174.3 mg sucrose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged-release capsules, hard
Venlafaxine Hydrochloride Prolonged-Release Capsules 75 mg:
White to off white spherical to oval pellets filled in Empty hard gelatin capsule shell (size ‘1’) of
Opaque Peach color cap and Opaque Peach color body imprinted with “E” on cap and “74” on the
body with edible black ink.
Venlafaxine Hydrochloride Prolonged-Release Capsules 150 mg:
White to off-white spherical to oval pellets filled in Empty hard gelatin capsule shell (size '0') of
Opaque Dark orange color cap and Opaque Dark orange color body imprinted with “E” on cap and
“89” on the body with edible black ink.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment of major depressive episodes.<br />For prevention of recurrence of major depressive episodes.<br />Treatment of generalised anxiety disorder.<br />Treatment of social anxiety disorder.<br />Treatment of panic disorder, with or without agoraphobia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Posology<br />Major depressive episodes<br />The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients<br />not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose<br />of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted<br />due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4<br />days.<br />Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical<br />evaluation (see section 4.4). The lowest effective dose should be maintained.<br />Patients should be treated for a sufficient period of time, usually several months or longer. Treatment<br />should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate<br />for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the<br />recommended dose in prevention of recurrence of MDE is the same as the one used during the current<br />episode.<br />Antidepressive medicinal products should continue for at least six months following remission.</p><p dir="ltr">Generalised anxiety disorder<br />The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients<br />not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose<br />of 225 mg/day. Dosage increases can be made at intervals of 2 weeks or more.<br />Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical<br />evaluation (see section 4.4). The lowest effective dose should be maintained.<br />Patients should be treated for a sufficient period of time, usually several months or longer. Treatment<br />should be reassessed regularly, on a case-by-case basis.<br />Social anxiety disorder<br />The recommended dose for prolonged-release venlafaxine is 75 mg given once daily. There is no<br />evidence that higher doses confer any additional benefit.<br />However, in individual patients not responding to the initial 75 mg/day, increases up to a maximum<br />dose of 225 mg/day may be considered. Dosage increases can be made at intervals of 2 weeks or more.<br />Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical<br />evaluation (see section 4.4). The lowest effective dose should be maintained. Patients should be treated<br />for a sufficient period of time, usually several months or longer. Treatment should be reassessed<br />regularly, on a case-by-case basis.<br />Panic disorder<br />It is recommended that a dose of 37.5 mg/day of prolonged-release venlafaxine be used for 7 days.<br />Dosage should then be increased to 75 mg/day. Patients not responding to the 75 mg/day dose may<br />benefit from dose increases up to a maximum dose of 225 mg/day. Dosage increases can be made at<br />intervals of 2 weeks or more.<br />Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical<br />evaluation(see section 4.4). The lowest effective dose should be maintained.<br />Patients should be treated for a sufficient period of time, usually several months or longer. Treatment<br />should be reassessed regularly, on a case-by-case basis.<br />Elderly patients<br />No specific dose adjustments of venlafaxine are considered necessary based on patient age alone.<br />However, caution should be exercised in treating the elderly (e.g., due to the possibility of renal<br />impairment, the potential for changes in neurotransmitter sensitivity and affinity occurring with aging).<br />The lowest effective dose should always be used, and patients should be carefully monitored when an<br />increase in the dose is required.<br />Paediatric population<br />Venlafaxine is not recommended for use in children and adolescents.<br />Controlled clinical studies in children and adolescents with major depressive disorder failed to<br />demonstrate efficacy and do not support the use of venlafaxine in these patients (see section 4.4 and<br />4.8). The efficacy and safety of venlafaxine for other indications in children and adolescents under<br />the age of 18 have not been established.</p><p dir="ltr">Patients with hepatic impairment<br />In patients with mild and moderate hepatic impairment, in general a 50% dose reduction should be<br />considered. However, due to inter-individual variability in clearance, individualisation of dosage may<br />be desirable.<br />There are limited data in patients with severe hepatic impairment. Caution is advised, and a dose<br />reduction by more than 50% should be considered. The potential benefit should be weighed against<br />the risk in the treatment of patients with severe hepatic impairment.<br />Patients with renal impairment<br />Although no change in dosage is necessary for patients with glomerular filtration rate (GFR) between<br />30-70 ml/minute, caution is advised. For patients that require haemodialysis and in patients with<br />severe renal impairment (GFR &lt; 30 ml/min), the dose should be reduced by 50%. Because of interindividual<br />variability in clearance in these patients, individualisation of dosage may be desirable.<br />Withdrawal symptoms seen on discontinuation of venlafaxine<br />Abrupt discontinuation should be avoided. When stopping treatment with venlafaxine, the dose should<br />be gradually reduced over a period of at least one to two weeks in order to reduce the risk of<br />withdrawal reactions (see sections 4.4 and 4.8). However, the time period required for tapering and<br />the amount of dose reduction may depend on the dose, duration of therapy and the individual patient.<br />In some patients, discontinuation may need to occur very gradually over periods of months or longer.<br />If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment,<br />then resuming the previously prescribed dose may be considered. Subsequently, the physician may<br />continue decreasing the dose, but at a more gradual rate.<br />Method of administration<br />For oral use<br />It is recommended that venlafaxine prolonged-release capsules be taken with food, at approximately<br />the same time each day. Capsules must be swallowed whole with fluid and not divided, crushed,<br />chewed, or dissolved.<br />Patients treated with venlafaxine immediate-release tablets may be switched to venlafaxine<br />prolonged-release capsules at the nearest equivalent daily dosage. For example, venlafaxine<br />immediate-release tablets 37.5 mg twice daily may be switched to venlafaxine prolonged-release<br />capsules 75 mg once daily. Individual dosage adjustments may be necessary.<br />Venlafaxine prolonged-release capsules contain spheroids, which release the active substance slowly<br />into the digestive tract. The insoluble portion of these spheroids is eliminated and may be seen in<br />faeces.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated
due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia.
Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an
irreversible MAOI.
Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible
MAOI (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Suicide/suicidal thoughts or clinical worsening<br />Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suiciderelated<br />events). This risk persists until significant remission occurs. As improvement may not occur<br />during the first few weeks or more of treatment, patients should be closely monitored until such<br />improvement occurs. It is general clinical experience that the risk of suicide may increase in the early<br />stages of recovery.<br />Other psychiatric conditions for which venlafaxine is prescribed can also be associated with an<br />increased risk of suicide related events. In addition, these conditions may be co-morbid with major<br />depressive disorder. The same precautions observed when treating patients with major depressive<br />disorder should therefore be observed when treating patients with other psychiatric disorders.<br />Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal<br />ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or<br />suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebocontrolled<br />clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed<br />an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than<br />25 years old.<br />Close supervision of patients, and in particular those at high risk, should accompany drug therapy,<br />especially in early treatment and following dose changes. Patients (and caregivers of patients) should<br />be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and<br />unusual changes in behaviour, and to seek medical advice immediately if these symptoms present.<br />Paediatric population<br />Venlafaxine should not be used in the treatment of children and adolescents under the age of 18 years.<br />Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly<br />aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among<br />children and adolescents treated with antidepressants compared to those treated with placebo. If, based<br />on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored<br />for the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents<br />concerning growth, maturation and cognitive and behavioural development are lacking.</p><p dir="ltr">Serotonin syndrome<br />As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition may<br />occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect<br />the serotonergic neurotransmitter system (including triptans, SSRIs, SNRIs, amphetamines, lithium,<br />sibutramine, St.John&#39;s Wort [Hypericum perforatum], fentanyl and its analogues, tramadol,<br />dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with medicinal agents that<br />impair metabolism of serotonin (such as MAOIs e.g. methylene blue), with serotonin precursors (such<br />as tryptophan supplements) or with antipsychotics or other dopamine antagonists (see sections 4.3<br />and 4.5).<br />Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations,<br />coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular<br />aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea,<br />vomiting, diarrhoea). Serotonin syndrome in its most severe form, can resemble NMS, which includes<br />hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs and<br />mental status changes.<br />If concomitant treatment with venlafaxine and other agents that may affect the serotonergic and/or<br />dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is<br />advised, particularly during treatment initiation and dose increases.<br />The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not<br />recommended.</p><p dir="ltr">Narrow-angle glaucoma<br />Mydriasis may occur in association with venlafaxine. It is recommended that patients with raised<br />intraocular pressure or patients at risk for acute narrow-angle glaucoma (angle-closure glaucoma) be<br />closely monitored.<br />Blood pressure<br />Dose-related increases in blood pressure have been commonly reported with venlafaxine. In some<br />cases, severely elevated blood pressure requiring immediate treatment has been reported in post<br />marketing experience. All patients should be carefully screened for high blood pressure and preexisting<br />hypertension should be controlled before initiation of treatment. Blood pressure should be<br />reviewed periodically, after initiation of treatment and after dose increases. Caution should be<br />exercised in patients whose underlying conditions might be compromised by increases in blood<br />pressure, e.g., those with impaired cardiac function.<br />Heart rate<br />Increases in heart rate can occur, particularly with higher doses. Caution should be exercised in<br />patients whose underlying conditions might be compromised by increases in heart rate.<br />Cardiac disease and risk of arrhythmia<br />Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or<br />unstable heart disease. Therefore, it should be used with caution in these patients.<br />In postmarketing experience, cases of QTc prolongation, Torsade de Pointes (TdP), ventricular<br />tachycardia, and fatal cardiac arrhythmias have been reported with the use of venlafaxine, especially<br />in overdose or in patients with other risk factors for QTc prolongation/TdP. The balance of risks and<br />benefits should be considered before prescribing venlafaxine to patients at high risk of serious cardiac<br />arrhythmia or QTc prolongation.</p><p dir="ltr">Convulsions<br />Convulsions may occur with venlafaxine therapy. As with all antidepressants, venlafaxine should be<br />introduced with caution in patients with a history of convulsions, and concerned patients should be<br />closely monitored. Treatment should be discontinued in any patient who develops seizures.<br />Hyponatraemia<br />Cases of hyponatraemia and/or the Syndrome of Inappropriate Antidiuretic Hormone (SIADH)<br />secretion may occur with venlafaxine. This has most frequently been reported in volume-depleted or<br />dehydrated patients. Elderly patients, patients taking diuretics, and patients who are otherwise<br />volume-depleted may be at greater risk for this event.<br />Abnormal bleeding<br />Medicinal products that inhibit serotonin uptake may lead to reduced platelet function. Bleeding<br />events related to SSRI and SNRI use have ranged from ecchymoses, hematomas, epistaxis, and<br />petechiae to gastrointestinal and life-threatening haemorrhages. The risk of haemorrhage may be<br />increased in patients taking venlafaxine. As with other serotonin-reuptake inhibitors, venlafaxine<br />should be used cautiously in patients predisposed to bleeding, including patients on anticoagulants<br />and platelet inhibitors. SSRIs/SNRIs may increase the risk of postpartum haemorrhage (see sections<br />4.6, 4.8).<br />Serum cholesterol<br />Clinically relevant increases in serum cholesterol were recorded in 5.3% of venlafaxine-treated<br />patients and 0.0% of placebo-treated patients treated for at least 3 months in placebo-controlled<br />clinical trials. Measurement of serum cholesterol levels should be considered during long-term<br />treatment.<br />Co-administration with weight loss agents<br />The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including<br />phentermine, have not been established. Co-administration of venlafaxine and weight loss agents is<br />not recommended. Venlafaxine is not indicated for weight loss alone or in combination with other<br />products.<br />Mania/hypomania<br />Mania/hypomania may occur in a small proportion of patients with mood disorders who have received<br />antidepressants, including venlafaxine. As with other antidepressants, venlafaxine should be used<br />cautiously in patients with a history or family history of bipolar disorder.<br />Aggression<br />Aggression may occur in a small number of patients who have received antidepressants, including<br />venlafaxine. This has been reported under initiation, dose changes and discontinuation of treatment.</p><p dir="ltr">As with other antidepressants, venlafaxine should be used cautiously in patients with a history of<br />aggression.<br />Discontinuation of treatment<br />Discontinuation effects are well known to occur with antidepressants, and sometimes these effects<br />can be protracted and severe. Suicide/suicidal thoughts and aggression have been observed in patients<br />during changes in venlafaxine dosing regimen, including during discontinuation. Therefore, patients<br />should be closely monitored when the dose is reduced or during discontinuation (see above in section<br />4.4 - Suicide/suicidal thoughts or clinical worsening, and Aggression). Withdrawal symptoms, when<br />treatment is discontinued, are common, particularly if discontinuation is abrupt (see section 4.8). In<br />clinical trials, adverse events seen on treatment discontinuation (tapering and post-tapering) occurred<br />in approximately 31% of patients treated with venlafaxine and 17% of patients taking placebo.<br />The risk of withdrawal symptoms may be dependent on several factors, including the duration and<br />dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including<br />paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety,<br />nausea and/or vomiting, tremor, headache, visual impairment and hypertension are the most<br />commonly reported reactions. Generally, these symptoms are mild to moderate; however, in some<br />patients they may be severe in intensity. They usually occur within the first few days of discontinuing<br />treatment, but there have been very rare reports of such symptoms in patients who have inadvertently<br />missed a dose. Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though<br />in some individuals they may be prolonged (2-3 months or more). It is therefore advised that<br />venlafaxine should be gradually tapered when discontinuing treatment over a period of several weeks<br />or months, according to the patient&#39;s needs (see section 4.2). In some patients, discontinuation could<br />take months or longer.<br />Akathisia/psychomotor restlessness<br />The use of venlafaxine has been associated with the development of akathisia, characterised by a<br />subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability<br />to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients<br />who develop these symptoms, increasing the dose may be detrimental.<br />Dry mouth<br />Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of caries,<br />and patients should be advised upon the importance of dental hygiene.<br />Diabetes<br />In patients with diabetes, treatment with an SSRI or venlafaxine may alter glycaemic control. Insulin<br />and/or oral antidiabetic dosage may need to be adjusted.</p><p dir="ltr">Sexual dysfunction<br />Selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake inhibitors (SNRIs)<br />may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting<br />sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs/SNRI.<br />Drug-Laboratory Test Interactions<br />False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have<br />been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests.<br />False positive test results may be expected for several days following discontinuation of venlafaxine<br />therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish<br />venlafaxine from PCP and amphetamine.<br />Sucrose<br />Binoven XL contains sugar spheres, containing sucrose. Patients with rare hereditary problems of<br />fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not<br />take this medicine.<br />Binoven XL contains Sodium<br />This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially<br />&#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Monoamine Oxidase Inhibitors (MAOI)<br />Irreversible non-selective MAOIs<br />Venlafaxine must not be used in combination with irreversible non-selective MAOIs. Venlafaxine<br />must not be initiated for at least 14 days after discontinuation of treatment with an irreversible nonselective<br />MAOI. Venlafaxine must be discontinued for at least 7 days before starting treatment with<br />an irreversible nonselective MAOI (see sections 4.3 and 4.4).<br />Reversible, selective MAO-A inhibitor (moclobemide)<br />Due to the risk of serotonin syndrome, the combination of venlafaxine with a reversible and selective<br />MAOI, such as moclobemide, is not recommended. Following treatment with a reversible MAOinhibitor,<br />a shorter withdrawal period than 14 days may be used before initiation of venlafaxine<br />treatment. It is recommended that venlafaxine should be discontinued for at least 7 days before starting<br />treatment with a reversible MAOI (see section 4.4).<br />Reversible, non-selective MAOI (linezolid)<br />The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to<br />patients treated with venlafaxine (see section 4.4).<br />Severe adverse reactions have been reported in patients who have recently been discontinued from an<br />MAOI and started on venlafaxine, or have recently had venlafaxine therapy discontinued prior to<br />initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea,<br />vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant<br />syndrome, seizures, and death.</p><p dir="ltr">Serotonin syndrome<br />As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may<br />occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect<br />the serotonergic neurotransmitter system (including triptans, SSRIs, SNRIs, amphetamines, lithium,<br />sibutramine, St. John&#39;s Wort [Hypericum perforatum], fentanyl and its analogues, tramadol,<br />dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with medicinal agents that<br />impair metabolism of serotonin (such as MAOIs e.g. methylene blue), with serotonin precursors (such<br />as tryptophan supplements) or with antipsychotics or other dopamine antagonists (see section 4.3 and<br />4.4).<br />If concomitant treatment with venlafaxine and an SSRI, an SNRI or a serotonin receptor agonist<br />(triptan) is clinically warranted, careful observation of the patient is advised, particularly during<br />treatment initiation and dose increases. The concomitant use of venlafaxine with serotonin precursors<br />(such as tryptophan supplements) is not recommended (see section 4.4).<br />CNS-active substances<br />The risk of using venlafaxine in combination with other CNS-active substances has not been<br />systematically evaluated. Consequently, caution is advised when venlafaxine is taken in combination<br />with other CNS-active substances.<br />Ethanol<br />Venlafaxine has been shown not to increase the impairment of mental and motor skills caused by<br />ethanol. However, as with all CNS-active substances, patients should be advised to avoid alcohol<br />consumption.<br />Drugs that Prolong the QT Interval<br />The risk of QTc prolongation and/or ventricular arrhythmias (e.g., TdP) is increased with concomitant<br />use of other medicinal products which prolong the QTc interval. Co-administration of such medicinal<br />products should be avoided (see section 4.4).<br />Relevant classes include:<br />&bull; class Ia and III antiarrhythmics (e.g. quinidine, amiodarone, sotalol, dofetilide)<br />&bull; some antipsychotics (e.g. thioridazine)<br />&bull; some macrolides (e.g. erythromycin)<br />&bull; some antihistamines<br />&bull; some quinolone antibiotics (e.g. moxifloxacin)</p><p>The above list is not exhaustive and other individual medicinal products known to significantly<br />increase QT interval should be avoided.<br />Effect of other medicinal products on venlafaxine<br />Ketoconazole (CYP3A4 inhibitor)<br />A pharmacokinetic study with ketoconazole in CYP2D6 extensive (EM) and poor metabolisers (PM)<br />resulted in higher AUC of venlafaxine (70% and 21% in CYP2D6 PM and EM subjects, respectively)<br />and O-desmethylvenlafaxine (33% and 23% in CYP2D6 PM and EM subjects, respectively)<br />following administration of ketoconazole. Concomitant use of CYP3A4 inhibitors (e.g., atazanavir,<br />clarithromycin, indinavir, itraconazole, voriconazole, posaconazole, ketoconazole, nelfinavir,<br />ritonavir, saquinavir, telithromycin) and venlafaxine may increase levels of venlafaxine and O<br />desmethylvenlafaxine. Therefore, caution is advised if a patient&#39;s therapy includes a CYP3A4<br />inhibitor and venlafaxine concomitantly.<br />Effect of venlafaxine on other medicinal products<br />Drugs Metabolized by Cytochrome P450 Isoenzymes<br />In vivo studies indicate that venlafaxine is a relatively weak inhibitor of CYP2D6. Venlafaxine did<br />not inhibit CYP3A4 (alprazolam and carbamazepine), CYP1A2 (caffeine), and CYP2C9<br />(tolbutamide) or CYP2C19 (diazepam) in vivo.<br />Lithium<br />Serotonin syndrome may occur with the concomitant use of venlafaxine and lithium (see Serotonin<br />syndrome).<br />Diazepam<br />Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its active<br />metabolite, desmethyldiazepam. Diazepam does not appear to affect the pharmacokinetics of either<br />venlafaxine or Odesmethylvenlafaxine. It is unknown whether a pharmacokinetic and/or<br />pharmacodynamics interaction with other benzodiazepines exists.<br />Imipramine<br />Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. There was a<br />dose dependent increase of 2-OH-desipramine AUC by 2.5 to 4.5-fold when venlafaxine 75 mg to<br />150 mg daily was administered. Imipramine did not affect the pharmacokinetics of venlafaxine and<br />O-desmethylvenlafaxine. The clinical significance of this interaction is unknown. Caution should be<br />exercised with co-administration of venlafaxine and imipramine.<br />Haloperidol<br />A pharmacokinetic study with haloperidol has shown a 42% decrease in total oral clearance, a 70%<br />increase in AUC, an 88% increase in Cmax, but no change in half-life for haloperidol. This should be taken into account</p><p>in patients treated with haloperidol and venlafaxine concomitantly.</p><p>The clinical significance of this interaction is unknown.<br />Risperidone<br />Venlafaxine increased the risperidone AUC by 50%, but did not significantly alter the<br />pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). The<br />clinical significance of this interaction is unknown.<br />Metoprolol<br />Concomitant administration of venlafaxine and metoprolol to healthy volunteers in a pharmacokinetic<br />interaction study for both medicinal products resulted in an increase of plasma concentrations of<br />metoprolol by approximately 30-40% without altering the plasma concentrations of its active<br />metabolite, &alpha;- hydroxymetoprolol. The clinical relevance of this finding in hypertensive patients is<br />unknown. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite,<br />O-desmethylvenlafaxine. Caution should be exercised with co-administration of venlafaxine and<br />metoprolol.<br />Indinavir<br />A pharmacokinetic study with indinavir has shown a 28% decrease in AUC and a 36% decrease in<br />Cmax for indinavir. Indinavir did not affect the pharmacokinetics of venlafaxine and Odesmethylvenlafaxine.<br />The clinical significance of this interaction is unknown.<br />Oral contraceptives<br />In post-marketing experience unintended pregnancies have been reported in subjects taking oral<br />contraceptives while on venlafaxine. There is no clear evidence these pregnancies were a result of<br />drug interaction with venlafaxine. No interaction study with hormonal contraceptives has been<br />performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pregnancy<br />There are no adequate data from the use of venlafaxine in pregnant women.<br />Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans<br />is unknown. Venlafaxine must only be administered to pregnant women if the expected benefits<br />outweigh any possible risk.<br />As with other serotonin reuptake inhibitors (SSRIs/SNRIs), discontinuation symptoms may occur in<br />the newborns if venlafaxine is used until or shortly before birth. Some newborns exposed to<br />venlafaxine late in the third trimester have developed complications requiring tube-feeding,<br />respiratory support or prolonged hospitalisation. Such complications can arise immediately upon<br />delivery.<br />Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late<br />pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN).<br />Although no studies have investigated an association of PPHN to SNRI treatment, this potential risk<br />cannot be ruled out with venlafaxine taking into account the related mechanism of action (inhibition<br />of the re-uptake of serotonin).<br />The following symptoms may be observed in neonates if the mother has used an SSRI/SNRI late in<br />pregnancy: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping.<br />These symptoms may be due to either serotonergic effects or exposure symptoms. In the majority of<br />cases, these complications are observed immediately or within 24 hours after partus.<br />Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following<br />SSRI/SNRI exposure within the month prior to birth (see sections 4.4, 4.8).</p><p dir="ltr">Breast-feeding<br />Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk. There<br />have been postmarketing reports of breast-fed infants who experienced crying, irritability, and<br />abnormal sleep patterns. Symptoms consistent with venlafaxine drug discontinuation have also been<br />reported after stopping breast-feeding. A risk to the suckling child cannot be excluded. Therefore, a<br />decision to continue/discontinue breast-feeding or to continue/discontinue therapy with venlafaxine<br />should be made, taking into account the benefit of breast-feeding to the child and the benefit of<br />venlafaxine therapy to the woman.<br />Fertility<br />Reduced fertility was observed in a study in which both male and female rats were exposed to Odesmethylvenlafaxine.<br />The human relevance of this finding is unknown (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any psychoactive medicinal product may impair judgment, thinking, and motor skills. Therefore, any<br />patient receiving venlafaxine should be cautioned about their ability to drive or operate hazardous<br />machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The most commonly (&gt;1/10) reported adverse reactions in clinical studies were nausea, dry mouth, headache and sweating (including night sweats).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Adverse reactions are listed below by system organ class and frequency.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to</p><p dir="ltr">&lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:665px"><tbody><tr><td><p><strong>Very Common</strong></p></td><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very Rare</strong></p></td><td><p><strong>Not Known</strong></p></td><td><p><strong>Body System</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Agranulocytosis*, Aplastic anaemia*, Pancytopaenia*, Neutropaenia*</p></td><td><p>Thrombocytopaenia*</p></td><td><p>&nbsp;</p></td><td><p>Blood and lymphatic system disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Anaphylactic reaction*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Immune system disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Inappropriate antidiuretic hormone secretion*</p></td><td><p>Blood prolactin increased*</p></td><td><p>&nbsp;</p></td><td><p>Endocrine disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Decreased appetite</p></td><td><p>&nbsp;</p></td><td><p>Hyponatraemia*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Metabolism and nutrition disorders</p></td></tr><tr><td><p>Insomnia</p></td><td><p>Confusional state*, Depersonalization*, Abnormal dreams, Nervousness, Libido decreased, Agitation*, Anorgasmia</p></td><td><p>Mania, Hypomania, Hallucination, Derealisation, Abnormal orgasm, Bruxism*, Apathy,</p></td><td><p>Delirium*</p></td><td><p>&nbsp;</p></td><td><p>Suicidal ideation and suicidal behaviours<sup>a</sup>, Aggression<sup>b</sup></p></td><td><p>Psychiatric disorders</p></td></tr><tr><td><p>Headache*<sup>c</sup>, Dizziness, Sedation</p></td><td><p>Akathisia*, Tremor, Paraesthesia, Dysgeusia</p></td><td><p>Syncope, Myoclonus, Balance disorder*, Coordination abnormal*, Dyskinaesia*</p></td><td><p>Neuroleptic Malignant Syndrome (NMS)*, Serotonin syndrome*, Convulsion, Dystonia*</p></td><td><p>Tardive dyskinaesia*</p></td><td><p>&nbsp;</p></td><td><p>Nervous system disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Visual impairment, Accommodation disorder, including vision blurred, Mydriasis</p></td><td><p>&nbsp;</p></td><td><p>Angle-closure glaucoma*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Eye disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tinnitus*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Vertigo</p></td><td><p>Ear and labyrinth disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Tachycardia, Palpitations*</p></td><td><p>&nbsp;</p></td><td><p>Torsade de pointes*, Ventricular tachycardia*, Ventricular fibrillation, Electrocardiogram QT prolonged*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Cardiac disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypertension, Hot flush</p></td><td><p>Orthostatic hypotension, Hypotension*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Vascular disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dyspnoea*, Yawning</p></td><td><p>&nbsp;</p></td><td><p>Interstitial lung disease*, Pulmonary eosinophilia*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td><p>Nausea, Dry mouth, Constipation</p></td><td><p>Diarrhoea*, Vomiting</p></td><td><p>Gastrointestinal haemorrhage*</p></td><td><p>Pancreatitis*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Gastrointestinal disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Liver function test abnormal*</p></td><td><p>Hepatitis*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Hepatobiliary disorders</p></td></tr><tr><td><p>Hyperhidrosis* (including night sweats) *</p></td><td><p>Rash, Pruritus*</p></td><td><p>Urticaria*, Alopecia*, Ecchymosis, Angioedema*, Photosensitivity reaction</p></td><td><p>Stevens-Johnson syndrome*, Toxic epidermal necrolysis*, Erythema multiforme*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hypertonia</p></td><td><p>&nbsp;</p></td><td><p>Rhabdomyolysis*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Musculoskeletal and connective tissue disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Urinary hesitation, Urinary retention,Pollakiuria *</p></td><td><p>Urinary incontinence</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Renal and urinary disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Menorrhagia*, Metrorrhagia*, Erectile dysfunction, Ejaculation disorder,</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Postpartum haemorrhaged*<sup>d</sup></p></td><td><p>Reproductive system and breast disorders</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Fatigue, Asthenia, Chills*</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Mucosal haemorrhage*</p></td><td><p>&nbsp;</p></td><td><p>General disorders and administration site conditions</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Weight decreased, Weight increased , Blood cholesterol increased</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Bleeding time prolonged*</p></td><td><p>&nbsp;</p></td><td><p>Investigations</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="ltr">*ADR identified post-marketing<br />a*Cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy<br />or early after treatment discontinuation (see section 4.4).<br />b** see section 4.4.<br />c***In pooled clinical trials, the incidence of headache with venlafaxine and placebo were similar.<br />d This event has been reported for the therapeutic class of SSRIs/SNRIs (see sections 4.4, 4.6).<br />Discontinuation of treatment<br />Discontinuation of venlafaxine (particularly when abrupt) commonly leads to withdrawal symptoms.<br />Dizziness, sensory disturbances (including paraethesia), sleep disturbances (including insomnia and<br />intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, vertigo, headache and flu<br />syndrome are the most commonly reported reactions. Generally, these events are mild to moderate<br />and are self-limiting; however, in some patients, they may be severe and/or prolonged. It is therefore<br />advised that when venlafaxine treatment is no longer required, gradual discontinuation by dose<br />tapering should be carried out. However, in some patients severe aggression, and suicidal ideation<br />occurred when the dose was reduced or during discontinuation (see sections 4.2 and 4.4).<br />Paediatric population<br />In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in children<br />and adolescents (ages 6 to 17) was similar to that seen for adults. As with adults, decreased appetite,<br />weight loss, increased blood pressure, and increased serum cholesterol were observed (see section<br />4.4).<br />In paediatric clinical trials the adverse reaction suicidal ideation was observed. There were also<br />increased reports of hostility and, especially in major depressive disorder, self-harm.<br />Particularly, the following adverse reactions were observed in paediatric patients: abdominal pain,<br />agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.</p><p dir="ltr">Reporting of suspected adverse reactions<br />&bull; Saudi Arabia<br />- The National Pharmacovigilance Center (NPC)<br />&bull; SFDA Call Center: 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa/<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In post marketing experience, overdose with venlafaxine was reported predominantly in combination<br />with alcohol and/or other medicinal products. The most commonly reported events in overdose<br />include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis,<br />convulsion, and vomiting. Other reported events include electrocardiographic changes (e.g.,<br />prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia,<br />bradycardia, hypotension, vertigo, and deaths.<br />Published retrospective studies report that venlafaxine over dosage may be associated with an<br />increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but<br />lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxinetreated<br />patients have a higher burden of suicide risk factors than SSRI patients. The extent to which<br />the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in<br />over dosage, as opposed to some characteristics of venlafaxine-treated patients, is not clear.<br />Prescriptions for venlafaxine should be written for the smallest quantity of the medicinal product<br />consistent with good patient management in order to reduce the risk of overdose.<br />Recommended treatment<br />General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs must<br />be monitored. When there is a risk of aspiration, induction of emesis is not recommended. Gastric<br />lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration<br />of activated charcoal may also limit absorption of the active substance. Forced diuresis, dialysis,<br />hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for<br />venlafaxine are known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Other antidepressants, ATC code: N06AX16<br />Mechanism of action<br />The mechanism of venlafaxine&#39;s antidepressant action in humans is believed to be associated with its<br />potentiation of neurotransmitter activity in the central nervous system. Preclinical studies have shown<br />that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin<br />and noradrenaline reuptake. Venlafaxine also weakly inhibits dopamine uptake. Venlafaxine and its<br />active metabolite reduce &beta;-adrenergic responsiveness after both acute (single dose) and chronic<br />administration. Venlafaxine and ODV are very similar with respect to their overall action on<br />neurotransmitter reuptake and receptor binding.<br />Venlafaxine has virtually no affinity for rat brain muscarinic, cholinergic, H1 histaminergic or &alpha;1-<br />adrenergic receptors in vitro. Pharmacological activity at these receptors may be related to various side<br />effects seen with other antidepressant medicinal products, such as anticholinergic, sedative and<br />cardiovascular side effects.<br />Venlafaxine does not possess monoamine oxidase (MAO) inhibitory activity.<br />In vitro studies revealed that venlafaxine has virtually no affinity for opiate or benzodiazepine sensitive<br />receptors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine<br />(ODV). Mean &plusmn; SD plasma half-lives of venlafaxine and ODV are 5&plusmn;2 hours and 11&plusmn;2 hours,<br />respectively. Steady-state concentrations of venlafaxine and ODV are attained within 3 days of oral<br />multiple-dose therapy. Venlafaxine and ODV exhibit linear kinetics over the dose range of 75 mg to<br />450 mg/day.<br />Absorption<br />At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine.<br />Absolute bioavailability is 40% to 45% due to presystemic metabolism. After immediate-release<br />venlafaxine administration, the peak plasma concentrations of venlafaxine and ODV occur in 2 and 3<br />hours, respectively. Following the administration of venlafaxine prolonged-release capsules, peak<br />plasma concentrations of venlafaxine and ODV are attained within 5.5 hours and 9 hours, respectively.<br />When equal daily doses of venlafaxine are administered as either an immediate-release tablet or<br />prolonged-release capsule, the prolonged-release capsule provides a slower rate of absorption, but the<br />same extent of absorption compared with the immediate-release tablet. Food does not affect the<br />bioavailability of venlafaxine and ODV.<br />Distribution<br />Venlafaxine and ODV are minimally bound at therapeutic concentrations to human plasma proteins<br />(27% and 30%, respectively). The volume of distribution for venlafaxine at steady-state is 4.4&plusmn;1.6<br />L/kg following intravenous administration.<br />Biotransformation<br />Venlafaxine undergoes extensive hepatic metabolism. In vitro and in vivo studies indicate that<br />venlafaxine is biotransformed to its major active metabolite, ODV, by CYP2D6. In vitro and in vivo<br />studies indicate that venlafaxine is metabolised to a minor, less active metabolite, Ndesmethylvenlafaxine,<br />by CYP3A4. In vitro and in vivo studies indicate that venlafaxine is a weak<br />inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2, CYP2C9, or CYP3A4.<br />Elimination<br />Venlafaxine and its metabolites are excreted primarily through the kidneys. Approximately 87% of a<br />venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%),<br />unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). Mean<br />&plusmn; SD plasma steady-state clearances of venlafaxine and ODV are 1.3&plusmn;0.6 L/h/kg and 0.4&plusmn;0.2 L/h/kg,<br />respectively.<br />Special populations<br />Age and gender<br />Subject age and gender do not significantly affect the pharmacokinetics of venlafaxine and ODV.<br />CYP2D6 extensive/poor metabolisers</p><p dir="ltr">Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive<br />metabolisers. Because the total exposure (AUC) of venlafaxine and ODV is similar in poor and<br />extensive metabolisers, there is no need for different venlafaxine dosing regimens for these two groups.<br />Hepatic impairment<br />In Child-Pugh A (mildly hepatically impaired) and Child-Pugh B (moderately hepatically impaired)<br />subjects, venlafaxine and ODV half-lives were prolonged compared to normal subjects. The oral<br />clearance of both venlafaxine and ODV was reduced. A large degree of intersubject variability was<br />noted. There are limited data in patients with severe hepatic impairment (see section 4.2).<br />Renal impairment<br />In dialysis patients, venlafaxine elimination half-life was prolonged by about 180% and clearance<br />reduced by about 57% compared to normal subjects, while ODV elimination half-life was prolonged<br />by about 142% and clearance reduced by about 56%. Dosage adjustment is necessary in patients with<br />severe renal impairment and in patients that require haemodialysis (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Studies with venlafaxine in rats and mice revealed no evidence of carcinogenesis. Venlafaxine was not<br />mutagenic in a wide range of in vitro and in vivo tests.<br />Animal studies regarding reproductive toxicity have found in rats a decrease in pup weight, an increase<br />in stillborn pups, and an increase in pup deaths during the first 5 days of lactation. The cause of these<br />deaths is unknown. These effects occurred at 30 mg/kg/day, 4 times the human daily dose of 375 mg<br />of venlafaxine (on an mg/kg basis). The no-effect dose for these findings was 1.3 times the human<br />dose. The potential risk for humans is unknown.<br />Reduced fertility was observed in a study in which both male and female rats were exposed to ODV.<br />This exposure was approximately 1 to 2 times that of a human venlafaxine dose of 375 mg/day. The<br />human relevance of this finding is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sugar spheres (containing sucrose)<br />Hypromellose<br />Talc<br />Ethyl cellulose<br />Shell contents<br />Cap<br />Gelatin<br />Iron oxide red (E172)<br />Titanium dioxide (E171)<br />Sodium lauryl sulfate<br />Body<br />Gelatin<br />Iron oxide red (E172)<br />Titanium dioxide (E171)<br />Sodium lauryl sulfate<br />Printing ink:<br />Shellac<br />Black iron oxide (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Binoven XL capsules are supplied in blister pack of 30 Capsules (10&rsquo;s blister x 3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aurobindo Pharma Saudi Arabia Limited,
Jeddah, Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>